Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
But, how quickly you see these results can depend heavily on which kind of B12 supplement you take
Does not include copper peptide synergy
From Zagreb to Longevity Clinics In my last edition, I covered BPC-157, the first peptide I ever learned about back in the 1990s while studying pharmacy in the former Yugoslavia
This serum is best suited for facial microneedling treatments where the goal is barrier repair, regeneration support, improved resilience, and visible firmness
Kinetic complementarity: The different half-lives (BPC-157 ~30 min vs TB-500 ~2-3 h) produce a layered tissue-repair signal: BPC-157 initiates early VEGF and angiogenic priming, while TB-500 sustains the cellular migration window for hours afterward